Xenetic Biosciences, Inc. (XBIO): Price and Financial Metrics

Xenetic Biosciences, Inc. (XBIO): $3.86

0.09 (+2.39%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add XBIO to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#230 of 468

in industry

XBIO Price/Volume Stats

Current price $3.86 52-week high $5.97
Prev. close $3.77 52-week low $2.87
Day low $3.85 Volume 1,000
Day high $3.91 Avg. volume 5,252
50-day MA $4.02 Dividend yield N/A
200-day MA $3.90 Market Cap 5.95M

XBIO Stock Price Chart Interactive Chart >


Xenetic Biosciences, Inc. (XBIO) Company Bio


Xenetic Biosciences, Inc. operates as a biopharmaceutical company. The Company focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens, as well as offers cell-based therapeutics targeting the B-cell receptor on the surface of malignant tumor cells. Xenetic Biosciences serves patients in the United States.


XBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

XBIO Latest Social Stream


Loading social stream, please wait...

View Full XBIO Social Stream

Latest XBIO News From Around the Web

Below are the latest news stories about XENETIC BIOSCIENCES INC that investors may wish to consider to help them evaluate XBIO as an investment opportunity.

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Key Insights Xenetic Biosciences will host its Annual General Meeting on 6th of December Total pay for CEO Jeff...

Yahoo | November 30, 2023

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platformDriving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid ...

Yahoo | November 10, 2023

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), ...

Yahoo | October 11, 2023

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

Yahoo | September 5, 2023

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 11, 2023

Read More 'XBIO' Stories Here

XBIO Price Returns

1-mo 8.73%
3-mo -11.26%
6-mo 15.56%
1-year 13.86%
3-year -82.53%
5-year -94.55%
YTD 11.88%
2023 21.01%
2022 -77.90%
2021 -36.76%
2020 41.67%
2019 -92.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!